.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,861,068

« Back to Dashboard

Details for Patent: 6,861,068

Title: Pharmaceutical compositions using semi-solid delivery vehicle
Abstract:A semi-solid delivery vehicle contains a polyorthoester and an excipient, and a semi-solid pharmaceutical composition contains an active agent and the delivery vehicle. The pharmaceutical composition may be a topical, syringable, or injectable formulation; and is suitable for local delivery of the active agent. Methods of treatment are also disclosed.
Inventor(s): Ng; Steven Y. (San Francisco, CA), Shen; Hui-Rong (Fremont, CA), Heller; Jorge (Woodside, CA)
Assignee: A.P. Pharma, Inc. (Redwood City, CA)
Filing Date:Jan 26, 2004
Application Number:10/765,768
Claims:1. A pharmaceutical composition, comprising: an active agent selected from mepivacaine, bupivacaine, dibucaine, procaine, lidocaine, tetracaine, antibiotics, antivirals, fungicides, scabicides or pediculicides, benzalkonium chloride, benzethonium chloride, chlorhexidine gluconate, mafenide acetate, methylbenzethonium chloride, nitrofurazone, nitromersol, estrogens, progestins, androgens, adrenocorticoids, insulin, erythropoietin, morphogenic proteins, bone morphogenic protein, aspirin, ibuprofen, naproxen, ketorolac, COX-1 inhibitors, COX-2 inhibitors, mechlorethamine, cyclophosphamide, fluorouracil, thioguanine, carmustine, lomustine, melphalan, chlorambucil, streptozocin, methotrexate, vincristine, bleomycin, vinblastine, vindesine, dactinomycin, daunorubicin, doxorubicin, tamoxifen, morphine, meperidine, codeine, combrestatin, contortrostatin, anti-VEGF, astringents, antiperspirants, irritants, rubefacients, vesicants, sclerosing agents, caustics, escharotics, keratolytic agents, sunscreens, hypopigmenting and antipruritic agents, fungicides, pesticides, herbicides, plant growth promoters or inhibitors, preservatives, disinfectants, air purifiers, nutrients, dexamethasone, cortisone, hydrocortisone, prednisone, prednisolone, beclomethasone, betamethasone, flunisolide, fluocinolone acetonide, fluocinonide, triamcinolone, flurogestone, medroxyprogesterone, norgestrel, norgestimate, norethindrone, fluorouracil and LHRH antagonists; and a semi-solid delivery vehicle comprising: a polyorthoester of formula I or formula II ##STR16## where: R is a bond, --(CH.sub.2).sub.a --, or --(CH.sub.2).sub.b --O--(CH.sub.2).sub.c --; where a is an integer of 1 to 10, and b and c are independently integers of 1 to 5; R* is a C.sub.1-4 alkyl; n is an integer of at least 5; and A is R.sup.1, R.sup.2, R.sup.3, or R.sup.4, where R.sup.1 is: ##STR17## where: p is an integer of 1 to 20; R.sup.5 is hydrogen or C.sub.1-4 alkyl; and R.sup.6 is: ##STR18## where: s is an integer of 0 to 30; t is an integer of 2 to 200; and R.sup.7 is hydrogen or C.sub.1-4 alkyl; R.sup.2 is: ##STR19## R.sup.3 is: ##STR20## where: x is an integer of 0 to 30; y is an integer of 2 to 200; R.sup.8 is hydrogen or C.sub.1-4 alkyl; R.sup.9 and R.sup.10 are independently C.sub.1-12 alkylene; R.sup.11 is hydrogen or C.sub.1-6 alkyl and R.sup.12 is C.sub.1-6 alkyl; or R.sup.11 and R.sup.12 together are C.sub.3-10 alkylene; and R.sup.4 is a diol containing at least one functional group independently selected from armide, imide, urea, and urethane groups; in which at least 0.1 mol percent of the A units are of the formula R.sup.1, and a pharmaceutically acceptable, polyorthoester-compatible liquid excipient selected from polyethylene glycol ether derivatives having a molecular weight between 200 and 4000, polyethylene glycol copolymers having a molecular weight between 400 and 4000, mono-, di-, or tri-glycerides of a C.sub.2-19 aliphatic carboxylic acid or a mixture of such acids, alkoxylated tetrahydrofurfuryl alcohols and their C.sub.1-4 alkyl ethers and C.sub.2-19 aliphatic carboxylic acid esters, and biocompatible oils.

2. The composition of claim 1, wherein the active agent is mepivacaine.

3. The composition of claim 2 where the concentration of the polyorthoester ranges from 1% to 99% by weight of the delivery vehicle.

4. The composition of claim 2 where the polyorthoester has a molecular weight between 1000 and 20,000.

5. The composition of claim 2 where the fraction of the A units that are of the formula R.sup.1 is between 1 and 90 mol percent.

6. The composition of claim 2 where the polyorthoester is of formula I, where: none of the units have A equal to R.sup.2 ; R.sup.3 is: ##STR21## where: x is an integer of 0 to 10; y is an integer of 2 to 30; and R.sup.6 is: ##STR22## where: s is an integer of 0 to 10; t is an integer of 2 to 30; and R.sup.5, R.sup.7, and R.sup.8 are independently hydrogen or methyl.

7. The composition of claim 6 where: R.sup.3 and R.sup.6 are both --(CH.sub.2 --CH.sub.2 --O).sub.2 --(CH.sub.2 --CH.sup.2)--; R.sup.5 is methyl; and p is 1 or 2.

8. The composition of claim 6 where: R.sup.3 and R.sup.6 are both --(CH.sub.2 --CH.sub.2 --O).sub.9 --(CH.sub.2 --CH.sub.2)--; R.sup.5 is methyl; and p is 1 or 2.

9. The composition of claim 2 where the fraction of the active agent is from 1% to 60% by weight of the composition.

10. The composition of claim 9 where the fraction of the active agent is from 5% to 30% by weight of the composition.

11. The composition of claim 2 where the composition is in topical, syringable, or injectable form.

12. A method of treating a disease state treatable by controlled release local administration of an active agent, comprising locally administering a therapeutically effective amount of the active agent in the form of a pharmaceutical composition of claim 1.

13. The method of claim 12 where the active agent is mepivacaine.

14. A method of preventing or relieving local pain at a site in a mammal, comprising administering to the site a therapeutically effective amount of a local anesthetic in the form of a pharmaceutically acceptable composition of claim 2.

15. A method of preventing or relieving local pain at a site in a mammal, comprising administering to the site a therapeutically effective amount of a local anesthetic in the form of a pharmaceutically acceptable composition of claim 9.

16. A process for the preparation of the pharmaceutical composition of claim 1 where the active agent is in solid form, comprising: optionally milling the active agent to reduce the particle size of the active agent; mixing the active agent and the delivery vehicle; and optionally milling the composition to reduce the particle size of the active agent.

17. The composition of claim 2, wherein the excipient is poly(ethylene glycol)monomethyl ether 550.

18. The composition of claim 2, wherein the excipient is a polyethylene glycol ether derivative having a molecular weight between 200 and 4000.

19. A method of preventing or relieving local pain at a site in a mammal, comprising administering to the site a therapeutically effective amount of a local anesthetic in the form of a pharmaceutically acceptable composition of claim 17.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc